1. Home
  2. RPC vs PHAT Comparison

RPC vs PHAT Comparison

Compare RPC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ridgepost Capital Inc. Class A Common Stock

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$8.76

Market Cap

978.4M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$8.87

Market Cap

969.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPC
PHAT
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
978.4M
969.8M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
RPC
PHAT
Price
$8.76
$8.87
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$11.00
$19.83
AVG Volume (30 Days)
557.7K
1.7M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
1.96%
N/A
EPS Growth
6.25
42.72
EPS
0.14
N/A
Revenue
$297,346,000.00
$175,110,000.00
Revenue This Year
$16.82
$93.04
Revenue Next Year
$15.80
$58.91
P/E Ratio
$61.64
N/A
Revenue Growth
0.30
216.93
52 Week Low
$6.79
$8.21
52 Week High
$9.51
$18.31

Technical Indicators

Market Signals
Indicator
RPC
PHAT
Relative Strength Index (RSI) 54.13 40.97
Support Level $8.08 $8.78
Resistance Level $8.86 $12.07
Average True Range (ATR) 0.37 0.49
MACD -0.04 0.04
Stochastic Oscillator 40.29 41.37

Price Performance

Historical Comparison
RPC
PHAT

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: